CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Costs and expenses:
Selling, general and administrative	242,000	292,000	371,000	652,000
Total	242,000	292,000	371,000	652,000
Operating loss	(242,000)	(292,000)	(371,000)	(652,000)
Total other expense
Loss from investments in unconsolidated entities, net	(269,000)	(998,000)	(267,000)	(1,131,000)
Total other expense	(269,000)	(998,000)	(267,000)	(1,131,000)
(Loss) income before income taxes	(511,000)	(1,290,000)	(638,000)	(1,783,000)
Provision for income taxes	0	1,000	0	3,000
Net (loss) income	(511,000)	(1,291,000)	(638,000)	(1,786,000)
Net loss attributable to noncontrolling interests	77,000	194,000	96,000	268,000
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc.	$ (434,000)	$ (1,097,000)	$ (542,000)	$ (1,518,000)
Basic net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc (in dollars per share)	$ (0.05)	$ (0.14)	$ (0.07)	$ (0.19)
Diluted net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc (in dollars per share)	$ (0.05)	$ (0.14)	$ (0.07)	$ (0.19)
Weighted average common shares outstanding, basic (in shares)	7,892,185	7,792,185	7,892,185	7,792,185
Weighted average common shares outstanding, diluted (in shares)	7,892,185	7,792,185	7,892,185	7,792,185